loading page

Anti-inflammatory and remyelinating effects of AZD4547 in experimental multiple sclerosis
  • +8
  • Fynn Gurski,
  • Kian Shirvanchi,
  • Vinothkumar Rajendran,
  • Ranjithkumar Rajendran,
  • Fevronia-Foivi Megalofonou,
  • Gregor Böttiger,
  • Christine Stadelmann,
  • Sudhanshu Bhushan,
  • Süleyman Ergün,
  • Srikanth Karnati,
  • Martin Berghoff
Fynn Gurski
Justus-Liebig-Universitat Giessen
Author Profile
Kian Shirvanchi
Justus-Liebig-Universitat Giessen
Author Profile
Vinothkumar Rajendran
Justus-Liebig-Universitat Giessen
Author Profile
Ranjithkumar Rajendran
Justus-Liebig-Universitat Giessen
Author Profile
Fevronia-Foivi Megalofonou
Justus-Liebig-Universitat Giessen
Author Profile
Gregor Böttiger
Justus-Liebig-Universitat Giessen
Author Profile
Christine Stadelmann
Georg-August-Universitat Gottingen Medizinische Fakultat
Author Profile
Sudhanshu Bhushan
Justus Liebig University Giessen Faculty of Medicine
Author Profile
Süleyman Ergün
Julius-Maximilians-Universitat Wurzburg
Author Profile
Srikanth Karnati
Julius-Maximilians-Universitat Wurzburg
Author Profile
Martin Berghoff
Justus-Liebig-Universitat Giessen

Corresponding Author:martinberghoff@t-online.de

Author Profile

Abstract

Background and Purpose: Fibroblast Growth Factor (FGF), VEGFR2, and CSF1R signalling pathways play a key role in the pathogenesis of multiple sclerosis (MS). Selective inhibition of FGFR by infigratinib in MOG35-55-induced EAE prevented severe first clinical episodes by 40%; inflammation and neurodegeneration were reduced, and remyelination was enhanced. Multi-kinase inhibition of FGFR1-3, CSF1R and VEGFR2 by AZD4547 may be more efficient in reducing inflammation, neurodegeneration and regeneration in the disease model. Experimental Approach: Female C57BL/6J mice were treated with AZD4547 (6.25 mg kg-1 or 12.5 mg kg-1) orally or placebo over 10 days either from time of EAE induction (prevention experiment) or onset of symptoms (suppression experiment). Effects on inflammation, neurodegeneration and remyelination were assessed at the peak of the disease (day 18/20 p.i.) and the chronic phase of EAE (day 41/42 p.i.). Key Results: In the prevention experiment, treatment with AZD4547 prevented severe first clinical episodes by 66.7 or 84.6% respectively. Mice treated with 12.5 mg kg-1 of AZD4547 hardly showed any symptoms in the chronic phase of EAE. In the suppression experiment, treatment with AZD4547 resulted in a long-lasting reduction of severe symptoms by 91 or 100%. Inflammation and demyelination were reduced, and axonal density, numbers of oligodendrocytes and their precursor cells, and remyelinated axons were increased in both experimental approaches. Conclusion and Implications: Multi-kinase inhibition by AZD4547 in a well-tolerated dose of 1 mg kg-1 in humans may be a promising approach to reduce inflammation and neurodegeneration, to slow down disease progression and support remyelination in patients.
Submitted to British Journal of Pharmacology
26 Apr 2024Assigned to Editor
26 Apr 2024Submission Checks Completed
29 Apr 2024Reviewer(s) Assigned
20 May 2024Review(s) Completed, Editorial Evaluation Pending
27 Jun 20241st Revision Received
05 Jul 2024Submission Checks Completed
05 Jul 2024Assigned to Editor
05 Jul 2024Review(s) Completed, Editorial Evaluation Pending
09 Jul 2024Reviewer(s) Assigned
15 Jul 2024Editorial Decision: Accept